Oramed Pharma (ORMP) Announces Submission of ORMD-0801 Phase 2b Protocol to U.S. FDA
Tweet Send to a Friend
Oramed Pharma (NASDAQ: ORMP) announced hat it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
